WO2000067697A3 - Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules - Google Patents
Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules Download PDFInfo
- Publication number
- WO2000067697A3 WO2000067697A3 PCT/FR2000/001259 FR0001259W WO0067697A3 WO 2000067697 A3 WO2000067697 A3 WO 2000067697A3 FR 0001259 W FR0001259 W FR 0001259W WO 0067697 A3 WO0067697 A3 WO 0067697A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- cells
- antibody conjugate
- delivering
- foreign
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44152/00A AU4415200A (en) | 1999-05-10 | 2000-05-10 | Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
EP00925426A EP1175498A2 (fr) | 1999-05-10 | 2000-05-10 | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
IL14639900A IL146399A0 (en) | 1999-05-10 | 2000-05-10 | Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
CA002373851A CA2373851A1 (fr) | 1999-05-10 | 2000-05-10 | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
JP2000616728A JP2002543810A (ja) | 1999-05-10 | 2000-05-10 | 外来性核酸を細胞に送達するための核酸−抗体複合体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR99/05943 | 1999-05-10 | ||
FR9905943A FR2793414B1 (fr) | 1999-05-10 | 1999-05-10 | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000067697A2 WO2000067697A2 (fr) | 2000-11-16 |
WO2000067697A3 true WO2000067697A3 (fr) | 2001-06-28 |
Family
ID=9545418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/001259 WO2000067697A2 (fr) | 1999-05-10 | 2000-05-10 | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1175498A2 (fr) |
JP (1) | JP2002543810A (fr) |
AU (1) | AU4415200A (fr) |
CA (1) | CA2373851A1 (fr) |
FR (1) | FR2793414B1 (fr) |
IL (1) | IL146399A0 (fr) |
WO (1) | WO2000067697A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2514536A1 (fr) * | 2003-01-31 | 2004-08-12 | Novartis Ag | Regulation negative d'un gene cible a l'aide de complexes de pei/oligoribonucleotide simple brin |
JP4521519B2 (ja) * | 2003-05-26 | 2010-08-11 | 学校法人慶應義塾 | 部分ヒストンテイル型イムノポーター |
FR2958645B1 (fr) * | 2010-04-09 | 2012-08-31 | Commissariat Energie Atomique | Hemi-anticorps a auto-assemblage |
US10540907B2 (en) | 2014-07-31 | 2020-01-21 | Intelligent Technologies International, Inc. | Biometric identification headpiece system for test taking |
US9959777B2 (en) | 2014-08-22 | 2018-05-01 | Intelligent Technologies International, Inc. | Secure testing device, system and method |
US10410535B2 (en) | 2014-08-22 | 2019-09-10 | Intelligent Technologies International, Inc. | Secure testing device |
WO2016073202A1 (fr) | 2014-11-04 | 2016-05-12 | Intelligent Technologies International, Inc. | Carte intelligente |
CN108530540B (zh) * | 2018-03-30 | 2021-06-15 | 华南农业大学 | 抗亚精胺单克隆抗体杂交瘤细胞株4e4及其单克隆抗体和应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988008854A1 (fr) * | 1987-05-06 | 1988-11-17 | Egbert Oosterwijk | Anticorps monoclonaux contre le carcinome des cellules renales |
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
WO1994004696A1 (fr) * | 1992-08-25 | 1994-03-03 | Miles Inc. | Apport nucleaire de macromolecules facilite par un signal de translocation |
WO1994013325A2 (fr) * | 1992-12-15 | 1994-06-23 | Microprobe Corporation | Sequences de liaison peptidiques pour l'amelioration de l'apport d'oligonucleotides |
US5428132A (en) * | 1987-10-11 | 1995-06-27 | United States Of America | Conjugate and method for integration of foreign DNA into cells |
WO1995021195A1 (fr) * | 1994-02-07 | 1995-08-10 | Research Development Foundation | Vecteur non viral |
WO1996013599A1 (fr) * | 1994-11-01 | 1996-05-09 | Winfried Wels | Systeme de transfert de l'acide nucleique |
WO1998002564A1 (fr) * | 1996-07-12 | 1998-01-22 | The John P. Robarts Research Institute | Vecteur hybride de virus herpetique/virus de epstein-barr |
WO1998047538A2 (fr) * | 1997-04-23 | 1998-10-29 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Colorants de synthese labiles aux acides et clivables par voie enzymatique pour le diagnostic avec de la lumiere dans le proche infrarouge et pour l'usage therapeutique |
WO1998056425A1 (fr) * | 1997-06-11 | 1998-12-17 | The School Of Pharmacy, University Of London | Compositions pharmaceutiques contenant des conjugues anticorps-enzymes combines a des promedicaments |
-
1999
- 1999-05-10 FR FR9905943A patent/FR2793414B1/fr not_active Expired - Fee Related
-
2000
- 2000-05-10 IL IL14639900A patent/IL146399A0/xx unknown
- 2000-05-10 WO PCT/FR2000/001259 patent/WO2000067697A2/fr active Search and Examination
- 2000-05-10 AU AU44152/00A patent/AU4415200A/en not_active Abandoned
- 2000-05-10 JP JP2000616728A patent/JP2002543810A/ja active Pending
- 2000-05-10 EP EP00925426A patent/EP1175498A2/fr not_active Withdrawn
- 2000-05-10 CA CA002373851A patent/CA2373851A1/fr not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
WO1988008854A1 (fr) * | 1987-05-06 | 1988-11-17 | Egbert Oosterwijk | Anticorps monoclonaux contre le carcinome des cellules renales |
US5428132A (en) * | 1987-10-11 | 1995-06-27 | United States Of America | Conjugate and method for integration of foreign DNA into cells |
WO1994004696A1 (fr) * | 1992-08-25 | 1994-03-03 | Miles Inc. | Apport nucleaire de macromolecules facilite par un signal de translocation |
WO1994013325A2 (fr) * | 1992-12-15 | 1994-06-23 | Microprobe Corporation | Sequences de liaison peptidiques pour l'amelioration de l'apport d'oligonucleotides |
WO1995021195A1 (fr) * | 1994-02-07 | 1995-08-10 | Research Development Foundation | Vecteur non viral |
WO1996013599A1 (fr) * | 1994-11-01 | 1996-05-09 | Winfried Wels | Systeme de transfert de l'acide nucleique |
WO1998002564A1 (fr) * | 1996-07-12 | 1998-01-22 | The John P. Robarts Research Institute | Vecteur hybride de virus herpetique/virus de epstein-barr |
WO1998047538A2 (fr) * | 1997-04-23 | 1998-10-29 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Colorants de synthese labiles aux acides et clivables par voie enzymatique pour le diagnostic avec de la lumiere dans le proche infrarouge et pour l'usage therapeutique |
WO1998056425A1 (fr) * | 1997-06-11 | 1998-12-17 | The School Of Pharmacy, University Of London | Compositions pharmaceutiques contenant des conjugues anticorps-enzymes combines a des promedicaments |
Non-Patent Citations (9)
Title |
---|
BIOCHEMICAL PHARMACOLOGY, vol. 40, no. 2, 1990, pages 253 - 264, ISSN: 0006-2952 * |
BIOCHEMISTRY AND CELL BIOLOGY, vol. 73, no. 11-12, 1995, pages 949 - 958, ISSN: 0829-8211 * |
CHAKRABARTI, M. ET AL: "Transfer of DNA into lymphoma cells by DNA-bound to T101- biotinylated -avidin- polylysine antibody complex.", JOURNAL OF NUCLEAR MEDICINE, (1996) VOL. 37, NO. 5 SUPPL., PP. 62P. MEETING INFO.: 43RD ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE DENVER, COLORADO, USA JUNE 3-5, 1996, XP002133111 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1990, HUCKETT B ET AL: "EVIDENCE FOR TARGETED GENE TRANSFER BY RECEPTOR-MEDIATED ENDOCYTOSIS STABLE EXPRESSION FOLLOWING INSULIN-DIRECTED ENTRY OF NEO INTO HEPG2 CELLS", XP002155196, Database accession no. PREV199090077976 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, TRAUT ROBERT R ET AL: "Location and domain structure of Escherichia coli ribosomal protein L7/L12: Site specific cysteine cross-linking and attachment of fluorescent probes.", XP002155195, Database accession no. PREV199698797154 * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; GUY J ET AL: "Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy.", XP002133112, retrieved from STN Database accession no. 96031841 * |
FOMINAYA J ET AL: "Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1996 MAY 3) 271 (18) 10560-8., XP002133110 * |
MOLECULAR BIOTECHNOLOGY, (1995 JUN) 3 (3) 237-48. REF: 60 * |
PONCET ET AL: "ANTIFECTION: AN ANTIBODY-MEDIATED METHOD TO INTRODUCE GENES INTO LYMPHOID CELLS IN VITRO AND IN VIVO", GENE THERAPY, vol. 3, 1996, pages 731 - 738, XP000877306 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000067697A2 (fr) | 2000-11-16 |
AU4415200A (en) | 2000-11-21 |
IL146399A0 (en) | 2002-07-25 |
JP2002543810A (ja) | 2002-12-24 |
FR2793414B1 (fr) | 2003-05-23 |
CA2373851A1 (fr) | 2000-11-16 |
EP1175498A2 (fr) | 2002-01-30 |
FR2793414A1 (fr) | 2000-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003020949A3 (fr) | Produits de recombinaison cibles d'acides nucleiques et utilisations en rapport avec lesdits produits | |
WO2001075087A8 (fr) | Variantes de lasubtilisine | |
WO2001062794A3 (fr) | Nouveaux canaux calciques humains 18607 | |
WO2001072976A3 (fr) | 32142, 21481, 25964, 21686, nouvelles molecules deshydrogenases humaines et utilisations | |
IL132951A0 (en) | Compounds preparation and use for transferring nucleic acids into cells | |
WO2003093469A3 (fr) | Procedes d'administration de molecules d'acides nucleiques dans des cellules et evaluation associee | |
AU1339701A (en) | Anti-cancer nucleic acid and protein targets | |
WO2001070777A3 (fr) | Genes de cotyledon2 feuillus et leurs utilisations | |
WO2003052117A3 (fr) | Procedes et produits relatifs a la transfection non virale | |
WO2000067697A3 (fr) | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules | |
EP1020529A3 (fr) | Vecteurs d'apport de gènes munis d'un tropisme pour les cellules des muscles lisses et/ou les cellules endothéliales | |
WO2002029057A3 (fr) | 32144, nouveau membre de la famille des amides hydrolases d'acide gras humaines | |
WO2001092493A3 (fr) | Nouvelles aminopeptidases humaines 21956 et 25856, et utilisations | |
CA2441535A1 (fr) | Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport | |
WO2004029075A3 (fr) | Acides nucleiques de peptides a recaptage et distribution dans les tissus ameliores | |
CA2375549A1 (fr) | Systeme d'apport de materiel biologique | |
WO2000011168A3 (fr) | Genes regulant les cellules souche hematopoietiques et utilisation de ces genes | |
AU2438501A (en) | Expression of proteins from amplified, immobilized nucleic acids | |
WO2001075076A3 (fr) | 33167, nouvelle hydrolase humaine, et utilisations associees | |
WO2002000857A3 (fr) | Acyltransférase humaine 53320 nouvellement découverte et ses utilisations | |
WO2002036167A8 (fr) | Formulations comprenant des polymeres de dextrine en combinaison avec des sucres pour l'introduction d'acides nucleiques | |
WO2002006485A3 (fr) | 47885, une nouvelle enzyme activant l'ubiquitine humaine et ses applications | |
WO2000053759A8 (fr) | Expression de l'alpha-fetoproteine humaine dans des cellules mammiferes | |
WO2002024898A3 (fr) | Nouvelle lipase humaine 47647 et utilisations | |
WO2000032803A3 (fr) | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000925426 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2373851 Country of ref document: CA Ref country code: CA Ref document number: 2373851 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 616728 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09926493 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000925426 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000925426 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |